IRCT20220111053692N2 IRCT 2022-06-07 Iran Hormone pharmaceutical Co. Bioequivalence study of valacyclovir 1000 mg tablet Bioequivalence study of valacyclovir 1000 mg tablet (Iran Hormone) versus VALTREX ® 1000 mg (GlaxoSmithKline) Tablet in healthy volunteers 2022-04-21 anticipated 24 Complete https://irct.ir/trial/63110 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other, Randomization description: A group of 24 people is then selected as the sample size using Excel software in a balanced way, one of the AB or BA sequences is randomly assigned to each candidate. They are then randomly divided into two groups of 12 and given to one group of test tablets and to the other group of reference tablets, Blinding description: This study is a Double-blind (participant) clinical trial. Valacyclovir and valterex tablets are removed from the package by the administrator and placed in similar and coded cans. Bioequivalence Bioequivalence study of valacyclovir 1000 mg tablet (Iran Hormone) versus VALTREX ® 1000 mg (GlaxoSmithKline) Tablet in healthy volunteers. Intervention 1: Intervention group: Receives one tablet of test drug (valaciclovir 1000 mg from Iran Hormone Pharmaceutical Company). Blood samples were taken from the volunteers for 24 hours at the mentioned times after drug administration and the drug concentration in plasma samples was measured by liquid chromatography with UV detector. Intervention 2: Control group: Receives one reference medicine tablet (Valtrex 1000 mg from GlaxoSmithKline). Blood samples were taken from the volunteers for 24 hours at the mentioned times after drug administration and the drug concentration in plasma samples was measured by liquid chromatography with UV detector. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information